{"protocolSection": {"identificationModule": {"nctId": "NCT04036110", "orgStudyIdInfo": {"id": "17-1809"}, "secondaryIdInfos": [{"id": "T32NR007091", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/T32NR007091"}], "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "Vitamin C Supplementation Intervention", "officialTitle": "Vitamin C Supplementation Intervention for Patients With Heart Failure-A Pilot Study"}, "statusModule": {"statusVerifiedDate": "2020-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-08-14", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-06-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-07-25", "studyFirstSubmitQcDate": "2019-07-25", "studyFirstPostDateStruct": {"date": "2019-07-29", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-12-15", "resultsFirstSubmitQcDate": "2020-12-15", "resultsFirstPostDateStruct": {"date": "2021-01-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-02-17", "lastUpdatePostDateStruct": {"date": "2021-03-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "collaborators": [{"name": "Sigma Theta Tau International Honor Society of Nursing", "class": "OTHER"}, {"name": "National Institute of Nursing Research (NINR)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study is to test a low-cost, simple vitamin C supplementation intervention, that is, comparing placebo to 500 mg/day vitamin C and 1 gram/day vitamin C daily to assess feasibility and acceptability of vitamin C supplementation and effects on serum vitamin C level, health-related quality of life (HRQOL), symptom burden, oxidative stress, and cardiac function.", "detailedDescription": "This study will address feasibility from the perspective of being able to: a) to detect significant differences in the serum vitamin C level after supplementation (3 months) between the intervention groups and the control group, b) to detect significant differences in health related quality of life (HRQOL), symptom burden, oxidative stress, and cardiac function after vitamin C supplementation (3 months) between the intervention groups and the control group."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Vitamin C supplementation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Intervention 1", "type": "EXPERIMENTAL", "description": "Vitamin C 500 mg taken daily for 3 months", "interventionNames": ["Dietary Supplement: Vitamin C 500 mg"]}, {"label": "Intervention 2", "type": "EXPERIMENTAL", "description": "Vitamin C 1000 mg taken daily for 3 months", "interventionNames": ["Dietary Supplement: Vitamin C 1000 mg"]}, {"label": "Control", "type": "PLACEBO_COMPARATOR", "description": "Placebo tablets taken daily for 3 months", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DIETARY_SUPPLEMENT", "name": "Vitamin C 500 mg", "description": "500 mg tablet taken orally with one meal daily", "armGroupLabels": ["Intervention 1"], "otherNames": ["L-Ascorbic acid"]}, {"type": "DIETARY_SUPPLEMENT", "name": "Vitamin C 1000 mg", "description": "1000 mg tablet taken orally with one meal daily", "armGroupLabels": ["Intervention 2"], "otherNames": ["L-Ascorbic acid"]}, {"type": "OTHER", "name": "Placebo", "description": "1 tablet taken orally with one meal daily", "armGroupLabels": ["Control"], "otherNames": ["Sugar pill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Serum Vitamin C Level at Baseline", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum", "timeFrame": "Baseline"}, {"measure": "Serum Vitamin C Level at Month 3", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum", "timeFrame": "Month 3"}], "secondaryOutcomes": [{"measure": "Health Related Quality of Life Scores", "description": "Health related quality of life is measured using the Minnesota Living with Heart Failure questionnaire (MLHFQ). The MLHFQ is a patient-reported outcome to measure the patient's perceptions of the influence of heart failure on physical and emotional aspects of life. The questionnaire has 21 items to assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and emotional functions. The response scale for all 21 items on the MLHFQ is based on a 6-point (from 0 to 5). Scores are summed to a range of 0-105, in which with higher scores indicate worse health-related quality of life. Measured at Baseline and Month 3.", "timeFrame": "Baseline and up to 3 months after enrollment"}, {"measure": "Total MSAS-HF Score", "description": "Symptom burden is measured using items from the Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF). The MSAS-HF is an 8-item questionnaire to measure HF symptoms experienced by patients with HF. Patients will be first asked if the symptom was present during the previous 7 days. If present, three characteristics of each symptom will be rated: frequency of symptom, severity of symptom, and degree of symptom distress. Frequency is rated on a scale from 0 to 5 (1=no symptom to 5=all the time), severity rated on a scale from 0 to 5 (0=not at all to 5=extremely) and distress rated on a scale from 0 to 5 (0=not at all to 5=extremely). Burden score for each symptom can range from 0 (no burden) to 4 (greatest symptom frequency, severity, and distress). The total MAS-HF scores are summed to a range of 0-180, with higher scores indicating higher symptom burden. Measured at Baseline and Month 3.", "timeFrame": "Baseline and up to 3 months after enrollment"}, {"measure": "Cardiac Function", "description": "The MindWare Mobile impedance cardiograph (model number 50-2303-00) used to measure participant's cardiac function using the parameter of cardiac output. Measured at Baseline and Month 3.", "timeFrame": "Baseline and up to 3 months after enrollment"}, {"measure": "Oxidative Stress", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify 8-iso-PGF2a isoprostane in serum to reflect oxidative stress. Measured at Baseline and Month 3.", "timeFrame": "Baseline and up to 3 months after enrollment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatents recruited will have a diagnosis of chronic HF, either preserved or reduced ejection fraction. The diagnosis and etiology of chronic HF will be confirmed by a HF cardiologist using established criteria.\n\nOther criteria:\n\n* have undergone evaluation of HF and optimization of medical therapy,\n* vitamin C supplementation \\<500 mg/day\n* have not been referred for heart transplantation,\n* able to read and speak English,\n* \\>1 month from any inpatient hospitalization\n\nExclusion Criteria:\n\n* history of renal stones or renal disease (serum creatinine \\>1.5,\n* history of glucose-6-phosphate dehydrogenase deficiency (G6PD) and cognitive impairment that precludes giving informed consent or ability to follow protocol instructions\n* pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "99 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jia-Rong Wu, PhD", "affiliation": "University of North Carolina, Chapel Hill", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UNCH Meadowmont Clinic", "city": "Chapel Hill", "state": "North Carolina", "zip": "27517", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}, "referencesModule": {"references": [{"pmid": "25360419", "type": "BACKGROUND", "citation": "Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014 Oct 16;4:283. doi: 10.3389/fonc.2014.00283. eCollection 2014."}, {"pmid": "11336107", "type": "BACKGROUND", "citation": "Ellis GR, Anderson RA, Chirkov YY, Morris-Thurgood J, Jackson SK, Lewis MJ, Horowitz JD, Frenneaux MP. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001 May;37(5):564-70. doi: 10.1097/00005344-200105000-00008."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "All of the individual participant data collected during the trial will be shared, after de-identification.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF"], "timeFrame": "Beginning 9 months and ending 36 months following article publication from this trial.", "accessCriteria": "Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Study briefly suspended due to administrative reasons.", "groups": [{"id": "FG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "FG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "FG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Study Suspended", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "BG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "BG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "30"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54", "spread": "18"}, {"groupId": "BG001", "value": "51", "spread": "14"}, {"groupId": "BG002", "value": "56", "spread": "8"}, {"groupId": "BG003", "value": "54", "spread": "14"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "27"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "19"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "16"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Serum Vitamin C Level at Baseline", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum", "populationDescription": "Data unreported for participants who refused to provide blood sample", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13372", "spread": "11555"}, {"groupId": "OG001", "value": "16079", "spread": "12564"}, {"groupId": "OG002", "value": "13111", "spread": "9135"}]}]}]}, {"type": "PRIMARY", "title": "Serum Vitamin C Level at Month 3", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum", "populationDescription": "Data unreported for participants who refused to provide blood sample", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Month 3", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "7"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21309", "spread": "11740"}, {"groupId": "OG001", "value": "20574", "spread": "13144"}, {"groupId": "OG002", "value": "12537", "spread": "7945"}]}]}]}, {"type": "SECONDARY", "title": "Health Related Quality of Life Scores", "description": "Health related quality of life is measured using the Minnesota Living with Heart Failure questionnaire (MLHFQ). The MLHFQ is a patient-reported outcome to measure the patient's perceptions of the influence of heart failure on physical and emotional aspects of life. The questionnaire has 21 items to assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and emotional functions. The response scale for all 21 items on the MLHFQ is based on a 6-point (from 0 to 5). Scores are summed to a range of 0-105, in which with higher scores indicate worse health-related quality of life. Measured at Baseline and Month 3.", "populationDescription": "Data unreported for some participants due to study suspended and lost to follow-up", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and up to 3 months after enrollment", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "10"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.3", "spread": "32.2"}, {"groupId": "OG001", "value": "31.4", "spread": "24.7"}, {"groupId": "OG002", "value": "44.2", "spread": "31.4"}]}]}, {"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.2", "spread": "23.2"}, {"groupId": "OG001", "value": "47.4", "spread": "37.9"}, {"groupId": "OG002", "value": "27.6", "spread": "27.6"}]}]}]}, {"type": "SECONDARY", "title": "Total MSAS-HF Score", "description": "Symptom burden is measured using items from the Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF). The MSAS-HF is an 8-item questionnaire to measure HF symptoms experienced by patients with HF. Patients will be first asked if the symptom was present during the previous 7 days. If present, three characteristics of each symptom will be rated: frequency of symptom, severity of symptom, and degree of symptom distress. Frequency is rated on a scale from 0 to 5 (1=no symptom to 5=all the time), severity rated on a scale from 0 to 5 (0=not at all to 5=extremely) and distress rated on a scale from 0 to 5 (0=not at all to 5=extremely). Burden score for each symptom can range from 0 (no burden) to 4 (greatest symptom frequency, severity, and distress). The total MAS-HF scores are summed to a range of 0-180, with higher scores indicating higher symptom burden. Measured at Baseline and Month 3.", "populationDescription": "Data unreported for some participants due to study suspended and lost to follow-up", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and up to 3 months after enrollment", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "10"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.5", "spread": "42.7"}, {"groupId": "OG001", "value": "20.2", "spread": "26.6"}, {"groupId": "OG002", "value": "31.2", "spread": "26.8"}]}]}, {"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.5", "spread": "33.3"}, {"groupId": "OG001", "value": "24.8", "spread": "41.4"}, {"groupId": "OG002", "value": "20.1", "spread": "30.0"}]}]}]}, {"type": "SECONDARY", "title": "Cardiac Function", "description": "The MindWare Mobile impedance cardiograph (model number 50-2303-00) used to measure participant's cardiac function using the parameter of cardiac output. Measured at Baseline and Month 3.", "populationDescription": "Data missing due to staff learning curve using the MindWare Mobile impedance cardiograph and technical problems to detect signal from participants with pacemaker devices which caused inability to measure impedance cardiograph.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline and up to 3 months after enrollment", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9"}, {"groupId": "OG002", "value": "5.6", "spread": "5.1"}]}]}, {"title": "Month 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.7"}, {"groupId": "OG002", "value": "14.2", "spread": "5.1"}]}]}]}, {"type": "SECONDARY", "title": "Oxidative Stress", "description": "The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify 8-iso-PGF2a isoprostane in serum to reflect oxidative stress. Measured at Baseline and Month 3.", "populationDescription": "Data unreported for participants who refused to provide blood sample", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline and up to 3 months after enrollment", "groups": [{"id": "OG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months"}, {"id": "OG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months"}, {"id": "OG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "7"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "23144", "spread": "44504"}, {"groupId": "OG001", "value": "10406", "spread": "27203"}, {"groupId": "OG002", "value": "13832", "spread": "20676"}]}]}, {"title": "3 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "507", "spread": "262"}, {"groupId": "OG001", "value": "2431", "spread": "3753"}, {"groupId": "OG002", "value": "2580", "spread": "2667"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From Baseline through the end of study, an approximate total of 3 months", "description": "Per study protocol section 8, only pre-specified events and those events that are potentially related to participation in this research study must be collected.", "eventGroups": [{"id": "EG000", "title": "Intervention 1 (500 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Intervention 2 (1000 mg)", "description": "Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}, {"id": "EG002", "title": "Control (Placebo)", "description": "Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Jia-Rong Wu, PhD, RN", "organization": "University of North Carolina at Chapel Hill", "email": "jiarong.wu2@uky.edu", "phone": "859-323-4712"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-04-21", "uploadDate": "2020-12-01T09:23", "filename": "Prot_SAP_000.pdf", "size": 754994}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000014815", "term": "Vitamins"}, {"id": "D000001205", "term": "Ascorbic Acid"}], "ancestors": [{"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000020011", "term": "Protective Agents"}], "browseLeaves": [{"id": "M17558", "name": "Vitamins", "asFound": "Period", "relevance": "HIGH"}, {"id": "M4513", "name": "Ascorbic Acid", "asFound": "Observed", "relevance": "HIGH"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "T437", "name": "Ascorbic Acid", "asFound": "Observed", "relevance": "HIGH"}, {"id": "T477", "name": "Vitamin C", "asFound": "Infected", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}